申请人:Takeda Pharmaceutical Company Limited
公开号:EP2264017A1
公开(公告)日:2010-12-22
The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like and useful as an sGC activation drug, or an agent for the prophylaxis and/or treatment of diseases such as hypertension, ischemic cardiac disease, cardiac failure, kidney disease, arteriosclerotic disease, atrial fibrillation, pulmonary hypertension, diabetes, diabetic complications, metabolic syndrome, peripheral arterial obstruction, erectile dysfunction and the like.
An sGC activation drug containing a compound represented by the formula (II):
wherein each symbol is as defined in the specification, or a salt thereof, as an active ingredient.
本发明旨在提供一种化合物,该化合物具有优异的药理作用、理化性质等,可用作sGC激活药物,或用于预防和/或治疗高血压、缺血性心脏病、心力衰竭、肾脏疾病、动脉硬化疾病、心房颤动、肺动脉高压、糖尿病、糖尿病并发症、代谢综合征、外周动脉阻塞、勃起功能障碍等疾病。
一种含有由式(II)代表的化合物的 sGC 激活药物:
其中各符号如说明书中所定义,或其盐作为活性成分。